SYNTHESIS OF PRIMERS AND DEVELOPMENT OF SIGNIFICANT GENES OF B.1.1.7 (ALPHA) VARIANT OF THE SARS-CoV-2 VIRUS

The threat of human infection with coronavirus became known back in the 60s of the last century. Since then, zoonotic coronavirus infection has spread among people and there were two major epidemics at the beginning of the 21st century. The rate of human infection with coronavirus infection spread rapidly and caused serious concern in the world. Coronavirus infection has undergone various genetic changes over time, as a result, in 2019, in Wuhan, China, coronavirus infection spread among people. Due to the widespread spread of coronavirus infection in the world, WHO declared a pandemic on March 11, 2020. Coronavirus infection SARS-CoV-2 has been registered in about 200 countries around the world and has undergone various genetic changes over time. Due to genetic changes, a new strain of coronavirus infection appeared in the UK in the autumn of 2020. To determine the genetic changes of coronavirus infection and to study them, 65 pairs of primers were developed in the Collective Use Laboratory to obtain the complete nucleotide sequence of the SARS-CoV-2 virus. Specific primers have been developed for the development of significant genes of the SARS-CoV-2 virus. The developed primers allow us to obtain complete information about the genes of SARS-CoV-2 viruses. The presented primers can be used for identification and development of the complete genome of the SARS-CoV-2 virus

1. Kahn J.S., McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24, Suppl: S223–S227, 2005. doi:10.1097/01.inf.0000188166.17324.60.

2. Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev, 2005. – Р. 635-664. doi:10.1128/MMBR.69.4.635-664.2005

3. Lu G., Wang Q., Gao1 G.F. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. – 2015. – Р. 468–478.

4. Sarah L., Andrew L., Aviv O. COVID-19: A review of the proposed pharmacological treatments. European Journal of Pharmacology, 2020. – Vol.886. – Р. 173-251.

5. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [Internet]. Geneva (Switzerland): World Health Organization; 2020 [cited 2020 Mar 11]. Available from: https://www.who.int/

6. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/table

7. Tracking SARS-CoV-2 variants https://www.who.int/en/activities/tracking-SARS-CoV-2 variants/

8. Explained: Why WHO named Covid-19 variants first found in India as ‘Kappa’ and ‘Delta’ | India News ‑ Times of India (англ.). The Times of India. Дата обращения: 20 января 2022.

9. WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern (англ.). www.who.int. Дата обращения: 20 января 2022

10. Rambaut A., Loman N., Pybus O., Barclay W., Barrett J., Carabelli A., Connor T., Peacock T., Robertson D.L., Volz E. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations.

11. Inside the B.1.1.7 Coronavirus Variant. https://www.nytimes.com/interactive/2021/health/coronavirus-mutations-B117-variant.html

12. Li D., Zhang J., Li J. Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2. Theranostics, 2020. – Р. 7150-62. https://doi.org/10.7150/thno.47649